PORTAGE,
Mich., USA, Sept. 20,
2024 /PRNewswire/ -- Stryker (NYSE: SYK), a
global leader in medical technologies, announced today that it has
completed the acquisition of NICO Corporation, a privately held
company providing a systematic approach to minimally invasive
surgery for tumor and intracerebral hemorrhage (ICH) procedures.
This acquisition further strengthens Stryker's commitment to
neurotechnology through tumor and stroke care.
ICH, or bleeding in the brain caused by a ruptured blood vessel,
is the deadliest form of stroke, affecting over 3.4 million people
annually around the world, with rising rates due to an aging
population.1,2 ICH has high morbidity and a 30-day
mortality rate ranging from 40-50%.3 NICO's
BrainPath® and Myriad® products
enable a treatment option for ICH with improved functional outcomes
compared to guideline-based medical management alone, the current
standard of care. 4,5
"The acquisition of NICO Corporation expands Stryker's portfolio
of solutions for tumor resection and the treatment of intracerebral
hemorrhage, the deadliest form of stroke," said Andy Pierce, group president, MedSurg and
Neurotechnology, Stryker. "As a global leader in neurosurgical
access and removal tools, this strategic addition enables us to
deliver differentiated, minimally invasive approaches that will
drive meaningful outcomes and improve the lives of patients
worldwide."
About Stryker
Stryker is a global leader in medical technologies and, together
with its customers, is driven to make
healthcare better. The company offers
innovative products and services in
MedSurg, Neurotechnology, Orthopaedics and Spine that help
improve patient and healthcare outcomes. Alongside its customers
around the world, Stryker impacts more than 150 million patients
annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Stryker
Senior Director, Communications
beth.sizemore@stryker.com
References
1 Sun T, Yuan Y, Wu K, et al. (2023) Trends and
patterns in the global burden of intracerebral hemorrhage: a
comprehensive analysis from 1990 to 2019. Frontiers in
Neurology. 14:1241158.
2 Katan M, Luft A. Global Burden of Stroke. Semin
Neurol. 2018 Apr;38(2):208-211. doi: 10.1055/s-0038-1649503. Epub
2018 May 23. PMID: 29791947.
3 Woo, D, Comeau ME, Venema SU, et al. (2022).
Risk Factors Associated With Mortality and Neurologic Disability
After Intracerebral Hemorrhage in a Racially and Ethnically Diverse
Cohort. JAMA Netw Open. 5(3):e221103
4 Pradilla G., Ratcliff, JJ, , Hall, AJ, et al.
(2024). Trial of Early Minimally Invasive Removal of
Intracerebral Hemorrhage. New England Journal of Medicine.
390(14), 1277-1289.
5 Greenberg, SM, Ziai WC, Cordonnier C., et al.
(2022) 2022 Guideline for the Management of Patients with
Spontaneous Intracerebral Hemorrhage: A Guideline from the American
Heart Association/American Stroke Association. Stroke.
53(7), e282-e361.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/stryker-completes-acquisition-of-nico-corporation-expanding-minimally-invasive-solutions-for-brain-tumor-removal-and-stroke-care-302253611.html
SOURCE Stryker